EQT nears 9.6 billion euro deal for Qiagen

EQT is nearing a 9.6 billion euro deal for molecular testing firm Qiagen, Bloomberg reported on Wednesday, after an earlier report that the Swedish buyout firm had submitted a binding offer of more than 50 dollars a share.

Why it matters: A deal at that size would take one of Europe's main diagnostics and sample preparation companies private, with Qiagen's board meeting this week and a competing bid from KKR still in the frame.

Data as of Bloomberg report of October 21, 2026 carried in the feed pool, and Reuters reporting of October 20, 2026 read in full, both resting on Bloomberg's account citing people familiar with the matter. Qiagen said it does not comment on market rumours or speculation, EQT did not immediately respond and KKR declined to comment, and the reports said there is no certainty a sale will result, so this item is single-sourced at the origin. Developing item.

EQT is nearing a 9.6 billion euro deal to acquire Qiagen, Bloomberg reported on Wednesday. Reuters, reporting Bloomberg’s earlier account on Tuesday, said EQT had submitted a binding offer of more than 50 dollars a share, KKR had also made a bid, and Qiagen’s board is meeting this week to decide, with no certainty the discussions will lead to a sale.

Qiagen, which develops molecular testing and sample preparation technologies used by research and clinical laboratories, had a market capitalisation of 8.57 billion euros in LSEG data cited by Reuters, and its US listed shares rose more than 6 percent on Tuesday. Qiagen said it does not comment on market rumours or speculation.

EQT nears 9.6 billion euro deal for Qiagen

Sources